Established Market Leader Polfa Tarchomin is one of the oldest and largest generic pharmaceutical companies in Poland, with a history dating back to 1823. Its long-standing presence and leadership in the anti-infectives, insulin, and psychotropic drugs markets present opportunities for partnerships, contract manufacturing, and expansion into new therapeutic segments.

Diverse Production Capabilities With 40 production lines producing various pharmaceutical forms including gels, aerosols, tablets, capsules, and insulin cartridges, Polfa Tarchomin demonstrates extensive manufacturing capacity. This scalability can facilitate collaborations for custom formulations, contract manufacturing, or supply chain expansion.

Regulatory Compliance The company’s adherence to strict GMP standards and possession of global quality certifications highlight its commitment to quality and compliance. This positions Polfa Tarchomin as a reliable partner for companies seeking manufacturing partners with proven regulatory standards and quality assurance.

Market Focus Areas Polfa Tarchomin specializes in prescription medications with strong market positions in anti-infectives, insulin, and dermatologicals, supplemented by over-the-counter products. There is potential to leverage their expertise in these segments for launching new formulations or expanding into emerging therapeutic markets.

Growth and Investment Potential Operating with an annual revenue between $25 million and $50 million and a workforce of up to 1,000 employees, Polfa Tarchomin offers room for strategic investments, technology upgrades, and distribution partnerships to support growth initiatives within Central and Eastern Europe.